-
-
-
-
-
-
-
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
-
-
-
-
-
-
-
RBC Capital on Gilead Sciences (GILD): 'What To Look For In Upcoming UC Readout'
-
-
-
-
-
-
-
PEPFAR and Global Fund expand lenacapavir access to 1 million more people
-
-
-
-
-
-
-
Oppenheimer on Gilead Sciences (GILD): 'Story Near-Term Remains Squarely HIV Focused'
-
-
-
-
-
-
-
Deutsche Bank stays Buy rated on Gilead Sciences (GILD) amid weekly scripts
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Gilead Sciences (GILD)
-
416,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

